Roth Capital analyst Debjit Chattopadhyay came out today with a favorable note on Sarepta Therapeutics Inc (NASDAQ:SRPT), following a negative article published in the Wall Street Journal …
Roth Capital analyst Debjit Chattopadhyay was out pounding the table on Sarepta Therapeutics Inc (NASDAQ:SRPT) Monday, reiterating a Buy rating and price target of $22, …
In a research report issued today, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on CTI BioPharma Corp (NASDAQ:CTIC) with a $4.50 price target, …
In a research note released today, Roth Capital research team, led by analyst Debjit Chattopadhyay, maintained a Buy rating on Alcobra Ltd (NASDAQ:ADHD) with a $10 price …
In a research report published Friday, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Sarepta Therapeutics Inc (NASDAQ:SRPT) with a price target of $22, as the …
Roth Capital analyst Debjit Chattopadhyay weighed in on Nektar Therapeutics (NASDAQ:NKTR), as the company will announce its financial results for the fourth-quarter on February 24, 2015. The …
Roth Capital’s healthcare analyst Debjit Chattopadhyay came out with a few comments on Agios Pharmaceuticals Inc (NASDAQ:AGIO), after the company reported a worse than expected fourth quarter results …
Roth Capital analyst Debjit Chattopadhyay was out pounding the table on Alcobra Ltd (NASDAQ:ADHD) Tuesday, reiterating a Buy rating and a price target …
In a research report sent to investors today, Roth Capital analyst Debjit Chattopadhyay maintained a Buy rating on Nektar Therapeutics (NASDAQ:NKTR) with a …
In a research report released this morning, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) with a $22 price …
